JNJ 67571244
Alternative Names: JNJ-1244; JNJ-67371244; JNJ-67571244Latest Information Update: 30 Jan 2024
At a glance
- Originator Genmab; Janssen Research & Development
- Developer Janssen Research & Development
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute myeloid leukaemia; Myelodysplastic syndromes
Most Recent Events
- 09 Dec 2023 Pharmacodynamics data from a preclinical study in Acute myeloid leukaemia presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 26 Jul 2022 Discontinued - Phase-I for Acute myeloid leukaemia (Second-line therapy or greater) in USA, Germany, Spain (IV)
- 26 Jul 2022 Discontinued - Phase-I for Myelodysplastic syndromes (Second-line therapy or greater) in USA, Germany, Spain (IV)